Statins reduce the risk of heart attack by roughly 36 to 37%, based on meta-analyses pooling data from large clinical trials. That number represents the relative risk reduction, meaning if a group of people would normally have 100 heart attacks over a given period, statin therapy would bring that number down to about 63. The actual benefit you experience depends on your baseline risk, how much your cholesterol drops, and how consistently you take the medication.
Relative vs. Absolute Risk Reduction
The 36-37% figure is a relative risk reduction, and it’s important to understand what that means in practical terms. If your chance of having a heart attack over the next 10 years is 20%, a 37% relative reduction brings that down to roughly 12.6%. That’s a meaningful absolute drop of about 7 percentage points. But if your baseline risk is only 5%, the same relative reduction lowers it to about 3.2%, an absolute difference of less than 2 percentage points.
This distinction matters because it shapes how much benefit you personally stand to gain. People at higher cardiovascular risk get more absolute benefit from statins, even though the relative reduction is similar across groups. One observational study of low- and medium-risk men found an absolute risk reduction of about 6 to 17 fewer cardiovascular events per 1,000 people treated over five years, depending on how strictly patients adhered to their prescriptions.
How LDL Cholesterol Drives the Benefit
The heart attack reduction from statins is closely tied to how far they push down LDL cholesterol, often called “bad” cholesterol. A large meta-analysis of 49 trials covering over 312,000 participants found that every 1 mmol/L drop in LDL (about 39 mg/dL) was associated with a 23% reduction in major vascular events. The more your LDL falls, the greater the protection.
Statins come in three intensity tiers based on how aggressively they lower LDL. Low-intensity regimens reduce LDL by less than 30%. Moderate-intensity doses lower it by 30 to just under 50%. High-intensity statins cut LDL by 50% or more. Current guidelines from the American College of Cardiology and the American Heart Association generally recommend high-intensity therapy for people who have already had a heart attack or stroke, have very high LDL (190 mg/dL or above), or carry a 10-year cardiovascular risk of 7.5% or higher.
Primary vs. Secondary Prevention
Primary prevention refers to people who have never had a heart attack or stroke. Secondary prevention covers those who already have. The research evidence is strong in both groups, but the absolute payoff differs substantially.
In primary prevention, a population-based study found that people who took their statins consistently (at least 70% of the time) saw cardiovascular risk drop by 16 to 30%, depending on their underlying risk level. Those in the 7.5-9.9% ten-year risk category saw about a 30% reduction, while those in the 10-19.9% range saw roughly 26%. For people at the lowest risk levels (under 5%), the benefit was smaller and less statistically certain.
In secondary prevention, relative reductions tend to be in a similar range, but because these patients start at much higher absolute risk, the number of heart attacks and deaths actually prevented is considerably larger. This is why guidelines are most emphatic about statin use for people who already have cardiovascular disease.
How Long Before Statins Start Working
Statins lower cholesterol within days of starting, but the reduction in heart attacks and strokes takes longer to show up. A meta-analysis of adults aged 50 to 75 without prior cardiovascular disease found that it takes approximately 2.5 years of treatment to prevent one major cardiovascular event for every 100 people treated. Some measurable benefit appeared as early as 8 months to 1.3 years in broader analyses, but the general window for meaningful protection is 1.5 to 3 years of consistent use.
This timeline has real implications. If you start a statin and stop after a few months because you feel fine or dislike taking a daily pill, you likely haven’t yet received the cardiovascular benefit the drug can provide. Statins are not a short-term fix; they work through sustained, long-term cholesterol lowering.
Effect on Overall Mortality
Beyond heart attacks specifically, statins also reduce the risk of dying from any cause. A systematic review of propensity-matched studies found that statin users had about a 28% lower risk of all-cause mortality compared to non-users. This is a notably large effect for a single medication class and reflects the broad impact of lowering LDL on heart attacks, strokes, and other vascular events that can be fatal.
Side Effects in Context
Muscle symptoms are the most commonly reported side effect. Between 10 and 25% of statin users mention muscle aches, cramps, or soreness at some point during treatment. However, controlled studies tell a more nuanced story. In one trial, 9.4% of people taking a statin reported muscle symptoms, compared to 4.6% of people taking a placebo. That suggests about half of the muscle complaints attributed to statins would have happened anyway, putting the true rate of statin-caused muscle symptoms closer to 5%.
There is also a small increase in the risk of developing type 2 diabetes with statin use, particularly at higher doses. But the cardiovascular benefit outweighs this risk considerably. For every 1,000 people treated with high-intensity statins per year, roughly 2 additional cases of diabetes occur while 6.5 cardiovascular events are prevented. For most people, that tradeoff strongly favors staying on the medication.
Who Benefits Most
The people who gain the most from statins are those with the highest baseline cardiovascular risk. This includes anyone who has already had a heart attack or stroke, people with LDL cholesterol of 190 mg/dL or higher, adults aged 40 to 75 with diabetes, and those whose estimated 10-year risk of a cardiovascular event reaches 7.5% or above. For these groups, the absolute number of heart attacks prevented is large enough that the case for treatment is strong.
For people at lower risk, the relative reduction in heart attacks is still real, but the absolute benefit is smaller. A 37% relative risk reduction sounds dramatic, and it is, but if your starting risk is very low, you’re reducing a small number by 37%. This is where individual factors like family history, cholesterol trajectory, and personal preferences become part of the decision.